Prescription Glimepiride Tablets Recalled Due to Tablet Misprint
Dr. Reddy's Laboratories is recalling Glimepiride 1mg tablets nationwide due to a printing defect on the tablet. The voluntary recall affects 14,425 bottles.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA classified this as a Class III recall for a minor tablet printing defect. No illnesses or injuries have been reported, and the hazard is limited to a labeling issue rather than a product safety defect.
Plain-English summary
Dr. Reddy's Laboratories, Inc. is recalling Glimepiride Tablets, USP 1mg due to a misprint on the tablet. The recall is voluntary and was initiated by the firm.
The affected product consists of 14,425 bottles of Glimepiride 1mg tablets distributed nationwide. The recalled lots are T2303609 and T2303610, both with an expiration date of June 2026. The product is manufactured by Dr. Reddy's Laboratories Limited in Srikakulam, India and is labeled for prescription use only.
Consumers and healthcare providers who have this medication should contact Dr. Reddy's Laboratories, Inc. with questions regarding the recall. No illnesses or injuries have been reported in connection with this defect. Patients should not discontinue their diabetes medication without consulting their healthcare provider.
The recalled product
- Product
- GLIMEPIRIDE (GLIMEPIRIDE)
- Brand
- GLIMEPIRIDE
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Category
- Drug
- Hazard
- mis-labeling
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot: T2303609
- Exp. 06/2026 Lot: T2303610
- Exp. 06/2026
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · GLIMEPIRIDE
- ModerateFDA Recalls Glimepiride Tablets for Misprint on Tablet
FDA (Drugs) · 2024-02-14
- ModerateFDA Recalls Glimepiride Tablets for Manufacturing Deviations
FDA (Drugs) · 2023-05-03
- ModeratePrescription Drug Glimepiride Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2023-05-03
- HighAccord Healthcare recalls Glimepiride tablets due to manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- ModerateGlimepiride 2 mg tablets recalled for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27